Investigational Drug Details
| Drug ID: | D583 |
| Drug Name: | Doxorubicin |
| Synonyms: | SA 033; SA 083 |
| Type: | Chemical drug |
| DrugBank ID: | -- |
| DrugBank Description: | -- |
| PubChem ID: | -- |
| CasNo: | -- |
| Repositioning for NAFLD: | No |
| SMILES: | -- |
| InChiKey: | -- |
| Molecular Weight: | -- |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | DNA intercalators; Type II DNA topoisomerase inhibitors |
| Therapeutic Category: | Enhance lipid metabolism |
| Clinical Trial Progress: | -- |
| Latest Progress: | Under investigation |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S02 | Enhance lipid metabolism | triglyceride-lowering; lipid tolerance; lipid metabolism | 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor; Decreases intestinal cholesterol absorption; FXR agonist; ACC inhibitor; FAS inhibitor; DGAT2 inhibitor; SCD-1 inhibitor | Atorvastatin; Ezetimibe; Obeticholic Acid; GS-9674; GS-0976; TVB-2640; IONIS-DGAT2rx; Aramchol; | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00271 | 35159219 | Cells | S-Adenosylmethionine: From the Discovery of Its Inhibition of Tumorigenesis to Its Use as a Therapeutic Agent. | Details |
| A03024 | 34159911 | Wiad Lek | THE EFFECT OF DOXORUBICIN-INDUCED OXIDATIVE STRESS ON CITRULLINE CONCENTRATION IN THE SMALL INTESTINAL MUCOSA AND PLASMA BLOOD IN RATS WITH NON-ALCOHOLIC STEATOHEPATITIS. | Details |
| A03274 | 34064765 | Cells | Anthracyclins Increase PUFAs: Potential Implications in ER Stress and Cell Death. | Details |
| A03620 | 33928009 | Clin Nephrol Case Stud | Severe type-B lactic acidosis in a patient with bilateral renal Burkitt's lymphoma. | Details |
| A03889 | 33832488 | Cell Commun Signal | Mild exacerbation of obesity- and age-dependent liver disease progression by senolytic cocktail dasatinib + quercetin. | Details |
| A08796 | 31981593 | Peptides | The new mechanism of Ghrelin/GHSR-1a on autophagy regulation. | Details |
| A12490 | 30425964 | Front Oncol | Senolytic Cocktail Dasatinib+Quercetin (D+Q) Does Not Enhance the Efficacy of Senescence-Inducing Chemotherapy in Liver Cancer. | Details |
| A14679 | 29290620 | Mol Metab | Pharmacological stimulation of p53 with low-dose doxorubicin ameliorates diet-induced nonalcoholic steatosis and steatohepatitis. | Details |
| A29224 | 34396545 | J Food Biochem | Nephroprotective activity of Vetiveria zizanioides (L.) Nash supplement in doxorubicin-induced nephrotoxicity model of Wistar rats. | Details |
| A37016 | 16714487 | Pharmacol Rev | The ATP-binding cassette transporters and their implication in drug disposition: a special look at the heart. | Details |
| A38510 | 11078796 | Int J Oncol | Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment. | Details |
| A38530 | 11032933 | Oncol Rep | Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. | Details |
| A39967 | 1931455 | Cancer Chemother Biol Response Modif | Gynecologic malignancies. | Details |
| A41044 | 6449280 | Cancer | Prediction of outcome in metastatic breast cancer treated with adriamycin combination chemotherapy. | Details |
| A41230 | 630530 | Cancer | Combination chemotherapy of metastatic breast cancer with vincristine adriamycin and prednisolone. | Details |
| A43830 | 30766960 | Hepatol Commun | Development of Hepatic Steatosis After Chemotherapy for Non-Hodgkin Lymphoma. | Details |
| A45926 | 22027652 | Pharmacogenet Genomics | Functional defect caused by the 4544G>A SNP in ABCC2: potential impact for drug cellular disposition. | Details |
| A48248 | 18765149 | Curr Oncol Rep | The impact of new data in the treatment of advanced hepatocellular carcinoma. | Details |